Mediplus Pharma is the pioneer of ozonized glycerin (OG), a proprietary ingredient developed over more than 50 years of research and technological innovation. Our ingredient remains stable at room temperature, and in 2022, novel compounds were discovered within it, leading to patents for its substances, manufacturing methods, applications, and formulations.
Since its registration as a cosmetic ingredient in 2004, OG has been widely used in skincare, and it was launched as an oral cosmetic ingredient in 2010. In 2023, the company established a dedicated production facility in Saitama, Japan, enabling high-quality mass production.
Beyond human health, Mediplus Pharma is committed to improving the well-being of animals by offering OG-based skincare and oral care products that complement pharmaceuticals and clinical treatments. 
OG is highly versatile and compatible with skin, oral tissues, scalp, hair, and mucous membranes. This allows for the development of low-irritation, high-performance formulations that were previously difficult to achieve.
Mediplus Pharma supplies OG raw materials and proprietary products to both domestic and international clients. These OG-based products are incorporated into private-label brands by partner companies.